Jeffrey Robert Ajer - 22 Sep 2021 Form 4 Insider Report for NEKTAR THERAPEUTICS (NKTR)

Role
Director
Signature
Mark A. Wilson, Attorney-in-Fact
Issuer symbol
NKTR
Transactions as of
22 Sep 2021
Net transactions value
-$65,164
Form type
4
Filing time
24 Sep 2021, 18:12:50 UTC
Previous filing
28 Oct 2021
Next filing
10 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NKTR Common Stock Award $0 +10,200 +39% $0.000000 36,175 22 Sep 2021 Direct F1, F2
transaction NKTR Common Stock Sale $65,164 -3,665 -10% $17.78* 32,510 22 Sep 2021 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NKTR Stock Option Award $0 +20,400 $0.000000 20,400 22 Sep 2021 Common Stock 20,400 $17.78 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.
F2 This RSU award vests in full, one year following September 22, 2021.
F3 Represents the number of shares required to be sold by the reporting person to cover tax obligations in connection with the vesting of certain RSUs held by the reporting person. This sale is mandated by the reporting person's previous election under the Issuer's equity incentive plans to require the satisfaction of tax obligations to be funded by a "sell to cover" transaction.
F4 This stock option vests in equal monthly installments over the one-year period beginning on September 22, 2021.